AstraZeneca (LON:AZN) Earns "Overweight" Rating from Barclays

AstraZeneca (LON:AZN - Get Free Report)'s stock had its "overweight" rating reaffirmed by stock analysts at Barclays in a research note issued on Monday, MarketBeat.com reports. They presently have a £125 ($158.21) price objective on the biopharmaceutical company's stock. Barclays's target price would suggest a potential upside of 17.81% from the stock's previous close.

Other analysts also recently issued research reports about the company. BMO Capital Markets restated an "outperform" rating on shares of AstraZeneca in a research note on Monday, February 12th. Jefferies Financial Group reaffirmed a "hold" rating and issued a £110 ($139.22) price target on shares of AstraZeneca in a report on Friday, February 16th. Shore Capital reaffirmed a "buy" rating on shares of AstraZeneca in a report on Friday. Berenberg Bank reaffirmed a "buy" rating on shares of AstraZeneca in a report on Wednesday, March 13th. Finally, JPMorgan Chase & Co. reaffirmed an "overweight" rating on shares of AstraZeneca in a report on Thursday. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of £115.88 ($146.66).

AstraZeneca Stock Performance

LON:AZN traded down GBX 10 ($0.13) during mid-day trading on Monday, hitting £106.10 ($134.29). 1,092,239 shares of the company's stock traded hands, compared to its average volume of 2,262,130. The firm has a 50 day moving average of £102.90 and a two-hundred day moving average of £104.31. AstraZeneca has a 12 month low of GBX 9,461 ($119.74) and a 12 month high of £123.92 ($156.84). The firm has a market capitalization of £164.46 billion, a price-to-earnings ratio of 3,513.25, a price-to-earnings-growth ratio of 0.87 and a beta of 0.17. The company has a current ratio of 0.82, a quick ratio of 0.59 and a debt-to-equity ratio of 75.70.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.